EA201800477A1 - DRUG FOR TREATMENT OF ONCOLOGICAL DISEASES - Google Patents
DRUG FOR TREATMENT OF ONCOLOGICAL DISEASESInfo
- Publication number
- EA201800477A1 EA201800477A1 EA201800477A EA201800477A EA201800477A1 EA 201800477 A1 EA201800477 A1 EA 201800477A1 EA 201800477 A EA201800477 A EA 201800477A EA 201800477 A EA201800477 A EA 201800477A EA 201800477 A1 EA201800477 A1 EA 201800477A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- drug
- cytostatics
- particles
- targeted delivery
- tumor tissues
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B1/00—Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Изобретение описывает новый противоопухолевый препарат, представляющий собой стабильные наночастицы из биодеградирующего полимера, включающие два цитостатических агента с различными механизмами действия и векторную молекулу для адресной доставки частиц в опухолевые ткани. Предпочтительно в лекарственную композицию также входят поверхностно-активное вещество и криопротектор. В качестве цитостатиков используются винкристин и метотрексат, в качестве векторной молекулы для адресной доставки частиц в опухолевые ткани - C-концевой домен альфа-фетопротеина. Изобретение обеспечивает существенное повышение эффективности и безопасности указанных цитостатиков. Лекарственное средство представляет собой образец готовой формы препарата, который по параметрам растворения, однородности, пирогенности, уровню эндобактериальных токсинов, стабильности, стерильности соответствует стандартам использования стерильных лекарственных форм для медицинского применения у человека. Показаниями к применению препарата могут являться острый и хронический миелоидный лейкоз, лимфобластный лейкоз и другие онкологические заболевания мягких тканей.The invention describes a new antitumor drug, which is a stable nanoparticles of a biodegradable polymer, including two cytostatic agents with different mechanisms of action and a vector molecule for targeted delivery of particles to tumor tissues. Preferably, the surfactant and cryoprotectant are also included in the pharmaceutical composition. Vincristine and methotrexate are used as cytostatics, and the C-terminal domain of alpha-fetoprotein is used as a vector molecule for targeted delivery of particles to tumor tissues. The invention provides a significant increase in the efficiency and safety of these cytostatics. The drug is a sample of the finished form of the drug, which according to the parameters of dissolution, uniformity, pyrogenicity, the level of endobacterial toxins, stability, sterility meets the standards for the use of sterile dosage forms for medical use in humans. Indications for use of the drug may be acute and chronic myeloid leukemia, lymphoblastic leukemia and other oncological diseases of soft tissues.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201800477A EA201800477A1 (en) | 2018-08-28 | 2018-08-28 | DRUG FOR TREATMENT OF ONCOLOGICAL DISEASES |
PCT/RU2018/000674 WO2020046163A1 (en) | 2018-08-28 | 2018-10-11 | Preparation for treating oncological diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201800477A EA201800477A1 (en) | 2018-08-28 | 2018-08-28 | DRUG FOR TREATMENT OF ONCOLOGICAL DISEASES |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201800477A1 true EA201800477A1 (en) | 2020-02-28 |
Family
ID=69636676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201800477A EA201800477A1 (en) | 2018-08-28 | 2018-08-28 | DRUG FOR TREATMENT OF ONCOLOGICAL DISEASES |
Country Status (2)
Country | Link |
---|---|
EA (1) | EA201800477A1 (en) |
WO (1) | WO2020046163A1 (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2285537C1 (en) * | 2005-04-05 | 2006-10-20 | Автономная некоммерческая организация "Институт молекулярной диагностики (АНО "ИнМоДи") | Antitumor peptide preparation based on alpha-fetoprotein fragment, its conjugate, pharmaceutical composition and method for treatment of hormone-dependent tumors |
PL2644594T3 (en) * | 2007-09-28 | 2018-01-31 | Pfizer | Cancer Cell Targeting Using Nanoparticles |
RU2451509C1 (en) * | 2011-03-31 | 2012-05-27 | Автономная некоммерческая организация "Институт Молекулярной Диагностики" (АНО "ИнМоДи) | Anti-tumour preparation |
-
2018
- 2018-08-28 EA EA201800477A patent/EA201800477A1/en unknown
- 2018-10-11 WO PCT/RU2018/000674 patent/WO2020046163A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2020046163A1 (en) | 2020-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201890159A1 (en) | METHODS OF TREATMENT OF HEMATOLOGICAL MALIGNANT NATIONAL FORMATION WITH THE HELP OF COMBINED THERAPY BY mTOR INHIBITOR IN THE FORM OF NANOPARTICLES | |
CL2017003457A1 (en) | Methods for treating solid tumors using combination therapy of the mtor nanoparticle inhibitor. | |
MX2019013701A (en) | Methods of enhancing drug delivery and effectiveness of therapeutic agents. | |
MX2017005259A (en) | Indole carboxamides compounds useful as kinase inhobitors. | |
CY1121698T1 (en) | LIQUID INHALATION PREPARATION CONTAINING RPL554 | |
TR201900649T4 (en) | Mrna therapy for the treatment of ocular diseases. | |
NI201000145A (en) | DERIVATIVES OF IMIDAZINE - [1, 2-b] - PYRIDAZINE FOR THE TREATMENT OF DISEASE MEDIATED BY TYROSINE KINASE C-MET. | |
MX2019012884A (en) | Combination therapy. | |
MX2017016134A (en) | Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease. | |
EA201490254A1 (en) | COMBINED TREATMENT OF HEPATITIS C | |
CO2023018231A2 (en) | Novel therapeutic administration residues and uses of these | |
UY32739A (en) | COMBINATIONS OF CHEMOTHERAPIC AGENTS AND ANTAGONISTS DLL4 AND ITS USES IN CANCER THERAPY | |
AR090972A1 (en) | METHOD TO TREAT AMD IN ANTI-VEGF THERAPY-RESISTANT PATIENTS | |
EA201691789A1 (en) | PHARMACEUTICAL COMPOSITIONS AND SALTS OF 1,2,4-OXADIAZOLBENZOIC ACID | |
EP3818991A3 (en) | Compositions and methods for treating diseases | |
BR112015006929A2 (en) | biodegradable drug delivery systems for sustained protein release | |
CY1122899T1 (en) | AQUEOUS FORMULATION INCLUDING PARACETAMOL AND IBUPROPHEN | |
EA201691570A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING DIAMINO-HETEROCYCLIC CARBOXAMIDE COMPOUND AS AN ACTIVE INGREDIENT | |
CO2022007814A2 (en) | Tyk2 pseudokinase ligands | |
EA201691656A2 (en) | THERAPEUTIC WAYS WITH THE USE OF NORIBOGOGINE AND RELATED COMPOUNDS | |
CY1111482T1 (en) | COMBINATION AZD2171 AND PERMETRAXED | |
MX2018010223A (en) | Combination therapy for treatment of ovarian cancer. | |
MX2023010711A (en) | Phenalkylamines and methods of making and using the same. | |
EA201600469A1 (en) | PHARMACEUTICAL PREPARATION FOR PREVENTION AND TREATMENT OF PROGRESSIVE PATTERNS | |
EA201891439A1 (en) | TRICYCLIC COMPOUNDS AND THEIR COMPOSITIONS AS A KINAZ INHIBITOR |